Stifel Financial Corp Reduces Stake in DexCom, Inc. (NASDAQ:DXCM)

Stifel Financial Corp lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 21.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 92,871 shares of the medical device company’s stock after selling 24,859 shares during the quarter. Stifel Financial Corp’s holdings in DexCom were worth $6,226,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom in the 2nd quarter valued at about $25,000. Sachetta LLC increased its holdings in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares during the last quarter. DT Investment Partners LLC increased its holdings in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 315 shares during the last quarter. Riverview Trust Co grew its stake in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares during the last quarter. Finally, ORG Partners LLC grew its stake in DexCom by 1,992.0% during the 2nd quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock worth $59,000 after buying an additional 498 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Royal Bank of Canada dropped their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Oppenheimer dropped their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Stifel Nicolaus raised their price target on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Citigroup raised their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Wells Fargo & Company raised their price target on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average price target of $98.00.

DexCom Stock Down 2.2 %

DXCM opened at $77.19 on Friday. The business’s fifty day moving average is $73.58 and its two-hundred day moving average is $84.99. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The company has a market cap of $30.15 billion, a price-to-earnings ratio of 46.22, a PEG ratio of 2.46 and a beta of 1.12. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.